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Transcriptional cofactors are integral to the proper function and regulation of nuclear receptors. Members of the peroxisome
proliferator-activated receptor (PPAR) family of nuclear receptors are involved in the regulation of lipid and carbohydrate
metabolism. They modulate gene transcription in response to a wide variety of ligands, a process that is mediated by transcrip-
tional coactivators and corepressors. The mechanisms by which these cofactors mediate transcriptional regulation of nuclear re-
ceptor function are still being elucidated. The rapidly increasing array of cofactors has brought into focus the need for a clear
understanding of how these cofactors interact in ligand- and cell-speciﬁc manners. This review highlights the diﬀerential eﬀects
of the assorted cofactors regulating the transcriptional action of PPARγ and summarizes the recent advances in understanding the
physiological functions of corepressors and coactivators.
Copyright © 2007 Emily Powell et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are a
subfamily of structurally similar members of the nuclear
hormone receptor superfamily [1]. However, unlike classi-
cal nuclear hormone receptors, PPARs do not bind their lig-
ands with high aﬃnity, but possess a relatively low bind-
ing aﬃnity for unsaturated fatty acids and a broad range
of compounds that includes eicosanoids and their metabo-
lites (notably prostaglandin PGJ2 and leukotriene LTB4) and
synthetic ligands such as ﬁbrates (a drug for treatment of
hyperlipidemia) and thiazolidinediones (TZDs, antidiabetic
drugs). Thus, these receptors are considered to be nutri-
ent sensors that regulate lipid and glucose metabolism in
adipocytesandothermetabolicallyactivetissues.PPARshave
also been shown to be involved in a diverse array of non-
metabolic functions including inﬂammation, tissue repair,
atherosclerosis, and cancer [2–4].
PPARγ is the most highly characterized member of this
subfamily and its regulation by nuclear receptor cofactors
will be the focus of this review. Two major splice variants
have been found; PPARγ1 is expressed in adipocytes, skele-
tal muscle, liver and heart tissue, while PPARγ2 is almost
exclusively found in adipose tissue [5]. Although PPARγ2
may be more adipogenic than PPARγ1[ 6, 7], both isoforms
are thought to be essential regulators of adipogenesis [8–
10]. A common model for adipogenesis 3T3-L1 cell dif-
ferentiation into adipocytes is mediated by PPARγ2[ 11].
This model has been used extensively to deﬁne the rela-
tionship between PPARγ and its cofactors. In addition to
adipogenesis, PPARγ has been shown to play a role in in-
sulin sensitivity, atherosclerosis, inﬂammation, and cancer
[12, 13].
1.1. Overviewofcofactorsinvolvedintranscriptional
regulationofPPARγ
PPARtransactivationisinducedbyligand-dependentandin-
dependent mechanisms. Ligand-dependent transactivation
is induced by ligand binding to the C-terminal activation
function (AF-2) domain [14]. The role of transcriptional co-
factors in ligand-independent transactivation is poorly un-
derstood and outside of the scope of this review. PPARs form
heterodimers with the retinoid X receptor (RXR) and bind
to PPAR response elements (PPREs) in enhancer sites of reg-
ulated genes [15]. In the absence of ligand, nuclear recep-
tor corepressors bind to these heterodimers and recruit hi-
stone deactylases (HDACs) to repress transcription. Ligand
binding induces a conformational change in the receptor
dimer which excludes corepressors from the complex [16].2 PPAR Research
Ligand binding also increases PPAR’saﬃnity for a number of
coactivators,whosebindingfacilitateschromatinremodeling
by histone modiﬁcation and nucleosome mobilization, lead-
ing to the recruitment of the basal transcription machinery
toPPARtargetgenes[17–19].TheshortmotifLXXLL,where
L is leucine and X is any amino acid, is necessary for many
coactivators to bind to nuclear receptors [20].This “NRbox”
i sf o u n di nt h em a j o r i t yo fn u c l e a rr e c e p t o rc o a c t i v a t o r sa n d
binds to a hydrophobic pocket in the nuclear receptor bind-
ing domain [21].
Cofactors that have been shown to interact directly with
PPARγ to initiate its transactivation include members of the
p160 family of coactivators, which includes SRC-1/NCoA1,
TIF2/GRIP1/NCoA2/SRC-2, and pCIP/ACTR/AIB1/SRC-3
[22]. While having weak histone acetyltransferase (HAT) ac-
tivities, the C-terminal activation domains of p160 proteins
appear to primarily serve as foundations upon which coac-
tivator complexes are assembled. The p160 family of coac-
tivators contains functional activation domains that recruit
factors such as cAMP responsive element binding protein
(CREB)bindingprotein(CBP)/p300viaactivationdomain1
(AD1). The CBP/p300 complex possesses promiscuous HAT
activity, which aids in remodeling chromatin to allow tran-
scriptional activation [23].
The prominent ATP-dependent chromatin remodeling
complex SWI/SNF includes components such as BAF250,
BAF57, BAF60a, and BRG1 [24]. The SWI/SNF complex is
thought to be targeted to nuclear receptor target genes upon
ligand induction by interaction with receptors, coactivators,
or the general transcription machinery [23]. This complex
has also been implicated in chromatin remodeling leading to
activation of the PPARγ promoter, thus regulating its expres-
sion and adipogenesis [25, 26].
The thyroid receptor associated protein (TRAP)/vitamin
D receptor interacting proteins (DRIP)/Mediator complex
contains subunits which interact with a variety of transcrip-
tion factors and serve as a bridge between the basal tran-
scriptional machinery and DNA-bound nuclear receptor co-
factors [27, 28]. The TRAP complex interacts with PPARγ
in a ligand-dependent fashion. This complex acts more di-
rectly on the general transcription machinery, as is evi-
dent by its ability to transactivate transcription on naked
DNA templates [29]. Furthermore, the TRAP complex in-
teracts with nuclear receptors through PPAR binding protein
(PBP)/TRAP220/DRIP205 [30]. Thus, TRAP220 is a critical
component of this complex and is required for transcrip-
tional activation of PPARγ [31].
The PPAR-gamma coactivator-1α(PGC-1α) is a unique
PPAR coactivator, which serves as a scaﬀolding protein to in-
tegrateavarietyofcoactivator[32].UpondockingtoPPARγ,
PGC-1α recruits HATs such as CBP/p300 and steroid recep-
tor coactivator 1 (SRC-1) to remodel chromatin and initi-
ate transcription [32, 33]. However, interaction of PGC-1α
and HAT proteins is not suﬃcient to activate gene tran-
scription; the C-terminal domain of PGC-1α also interacts
with the TRAP complex through direct association with
PBP/TRAP220 to induce transcription (Wallberg et al. [33]).
PGC-1α has several RNA recognition motifs (RRM), which
function in the coupling of transcription to mRNA splicing
[34]. The modes of regulation of PPARγ by PGC-1α have
been reviewed [35, 36].
Although much is known about the mechanisms by
which PPARγ recruits coactivators to initiate transcription,
considerably less has been demonstrated with regard to tran-
scriptional repression by corepressors. Both NCoR (nuclear
receptor corepressor protein) [37] and SMRT (silencing me-
diator of retinoid and thyroid hormone receptors) [38] di-
rectly interact with PPARγ in vitro [39–41]. It may be noted
that PPARγ does not appear to be a strong repressor, how-
ever, increasing evidence suggests that NCoR and SMRT do
repress PPARγ-modulated gene expression during adipoge-
nesis [42, 43].
The exchange of cofactors may be facilitated by nu-
clear corepressor exchange factors (NCoEx), namely, trans-
ducin β-like 1 (TBL1) and the related protein TBLR1 [44].
TBL1 and TBLR1 are components of the NCoR corepres-
sor complex [45]. However, they activate PPARγ-dependent
transcription in response to rosiglitazone. Moreover, em-
bryonic stem cells with a TBL1 deletion fail to diﬀerentiate
into adipocytes [46] suggesting that TBL1 is necessary for
PPARγ activation. The mechanism of TBL1/TBLR1 activa-
tion of PPARγ remains elusive, but is probably linked to the
proteasome-dependent degradation of corepressors [46].
1.2. Physiologicalfunctionsofcofactorsin
adipogenesis
The molecular modes of regulation of nuclear receptor sig-
naling by cofactors have been extensively reviewed [16, 17,
23,47–49]. Herein wefocuson the recentadvancesin under-
standing the physiological functions of cofactors in PPARγ-
modulated processes, in particular, adipogenesis and energy
metabolism.ThediversiﬁedfunctionsofPPARγcofactorsare
studied in cell-based system and/or mice models, which are
summarized in Table 1.
2. COACTIVATORS
2.1. PGC-1αamasterregulatorofadaptive
thermogenesisinbrownadiposetissue
The thermogenic eﬀect of PPARγ in brown adipose tissue
(BAT) is mediated by PGC-1α, which is induced by cold and
highly expressed in BAT [35, 36]. PGC-1α regulates the ac-
tion of PPARγ on adaptive thermogenesis and fatty acid ox-
idation by interacting with the PPARγ/RXRα heterodimer.
This interaction stimulates expression of uncoupling protein
1 (UCP-1), which is responsible for uncoupling β-oxidation
from ATP synthesis in oxidative phosphorylation, ultimately
resulting in the loss of energy as heat [32].
PGC-1α is unique in that, in addition to its ligand-
dependent binding to the PPARγ ligand-binding domain
(LBD), it can also bind to the DNA-binding domain (DBD)
and the hinge region of nuclear receptors in a ligand-
independent fashion [59]. The ligand-independent bindingEmily Powell et al. 3
Table 1: Loss-of-function studies on PPARγ cofactors in adipogenesis and energy metabolism
PPARγ cofactor Phenotype in the absence of the cofactor
Cell-based studies Mouse studies
Brg1, hBrm (SWI/SNF components)
Blocked adipogenesis (Salma et al. [25])
—
R e d u c e dp r e s e n c eo fP o lI Ia n dG T F s
on the promoter (Salma et al. [25])
Decreased PPARγ transcription
(Salma et al. [25])
TIF2 Increased lipolysis (Picard et al. [50])
Enhanced adaptive thermogenesis (Picard et al. [50])
Protection against obesity (Picard et al. [50])
Increased insulin-sensitivity (Picard et al. [50])
Improved metabolic proﬁle. Increased lipolysis
(Picard et al. [50])
Decreased presence of PPARγ
SRC-1 —
Predisposition to obesity (Picard et al. [50])
Reduced energy expenditure (Picard et al. [50])
Reduced fatty acid oxidation in brown adipose
tissue (Picard et al. [50])
Decreased energy expenditure, attenuated fatty
acid oxidation (Picard et al. [50])
SRC-1/pCIP double knockout
Abrogated preadipocyte diﬀerentiation
(Wang et al. [51]) Diminished lipid storage in brown fat; increased
caloric intake on both chow and high-fat diet due
to increased leptin levels; resistance to
diet-induced obesity; increased basal metabolic
rate and energy expenditure (Wang et al.[51])
Reduced expression of PPARγ-target
genes, including UCP-1, due to
corepressor recruitment and decreased
PPARγ recognition of PPREs
(Wang et al. [51])
PGC-1α
Impaired induction of thermogenic
genes in BAT (Uldry et al. [52]) Reduced mitochFondrial function (Lin et al. [53])
Decreased number and impaired
function of mitochondria
(Uldry et al.[52])
Resistance to obesity and hyperactivity (Lin et al.
[53])
TRAP220/DRIP205/PBP
Defective PPARγ-stimulated
adipogenesis (Ge et al. [31])
Defective vascular development similar to that
seen in PPARγ-null mice (Barak et al. [54];
Zhu et al. [55])
PRIP/NRC/RAP250/TRBP
Decreased PPARγ-mediated
transcriptional activation
(Antonson et al. [56]; Zhu et al. [57])
—
RIP140
Upregulation of genes involved in
energy dissipation (Poweka et al.,
2006)
Increased oxygen consumption and resistance to
high-fat diet-induced obesity (Leonardsson et al.
[58])
Increased PGC-1α expression
(Poweka et al., 2006)
Expression of lipgenic enzymes is decreased.
UCP-1 (involved in energy dissipation in BAT)
expression is increased (Leonardsson et al. [58])
NCoR and SMRT Increased adipocyte diﬀerentiation
(Yu et al. [42]) —
Sirt1 Decreased NCoR levels (Picard et al. [43]) —
of PGC-1α to PPARγ is mediated by the PGC-1α N-terminal
domain and results in the expression of enzymes involved
in the mitochondrial respiratory chain to activate adaptive
thermogenesis [32, 60]. Chromatin immunoprecipitation
(ChIP) analyses revealed that the presence of PGC-1α de-
creases the association of corepressors on a PPRE-containing
gene in the absence of exogenous ligand without altering the
bindingofPPARγ,andPGC-1αissuﬃcienttorecruitSRC-1,
p300, and RNA polymerase II to the PPRE-containing gene
in the absence of rosiglitazone [61].
The ectopic expression of PGC-1α in white adipose tis-
sue (WAT) in vitro causes induction of the genes associated
with the brown fat phenotype, such as UCP-1 and compo-
nents of the electron transport chain [62, 63]. The presence4 PPAR Research
of UCP-1 in WAT is associated with a more brown-fat like
phenotype, enhanced metabolic rate and insulin sensitivity,
and resistance to obesity [64–66], which could indicate a po-
tential therapeutic role for PGC-1α and UCP-1.
The function of PGC-1α in adaptive energy metabolism
is reinforced in the PGC-1α knockout mouse model [53].
PGC-1α null mice are born with no obvious defects dur-
ingembryonicdevelopmentbuthavereducedmitochondrial
function. Intriguingly, null mice are lean and resistant to
diet-inducedobesity.Theleanphenotypeislargelyduetohy-
peractivitycausedbylesionsinthestriatalregionofthebrain
w h i c hc o n t r o l sm o v e m e n t[ 53]. The closely related family
member PGC-1β has been less studied, but it appears to in-
duce mitochondrial biogenesis and fatty acid oxidation in
several cell types [67–69]. Thus, PGC-1β can regulate some
but not all activities of PGC-1α. The most recent PGC-1β
knockdown studies in immortal preadipocyte lines derived
from PGC-1α null mice reveal complementary actions of the
two PGC-1 proteins [52]. Loss of PGC-1α alone severely im-
pairs the induction of thermogenic genes but does not aﬀect
brown fat diﬀerentiation (Figure 1). Loss of either PGC-1α
or PGC-1β exhibits a small decrease in the diﬀerentiation-
induced mitochondrial biogenesis; however, double knock-
downresultsinareducednumberofmitochondriaandfunc-
tionaldefects[52].ThisstudyimplicatesthatPGC-1β playsa
role in brown fat diﬀerentiation, and is at least as important
as PGC-1α in this process (Figure 1).
2.2. Effectsofthep160coregulatorsSRC-1,
TIF2/SRC-2,andp/CIP/SRC-3onenergy
metabolismandhomeostasis
Members of the 160kd protein family of coactivators are
able to interact directly with the AF2 domain of PPARγ to
allow nuclear receptor transactivation function in a ligand-
dependent manner via an α-helical LXXLL motif on p160
protein’s N-terminal domain. Furthermore, CBP/p300 inter-
acts with p160 cofactors and directly with PPARγ, possibly
providing additional stability to the complex through an in-
creased number of contact points [70]. However, although
CBP/p300 binding is required for maximal PPARγ activity in
vitro, minimal data exists showing a requirement for these
cofactors in adipogenesis [71].
Mice deﬁcient in p160 family members exhibit very dif-
ferent phenotypes, providing insights into their physiologi-
cal functions in adipogenesis and energy metabolism [50].
TIF2−/− mice exhibit enhanced adaptive thermogenesis and
protection against obesity, whereas SRC-1−/− mice are pre-
disposed to obesity with accompanying reduced energy ex-
penditure [50]. TIF2−/− mice also show improved metabolic
proﬁles and increased whole-body insulin sensitivity [50].
TIF2 seems to have a greater inﬂuence on the p300/PPARγ
complex than does the SRC-1 complex, which could possi-
bly be attributed to a weaker capacity of SRC-1 to interact
with other coregulators such as p300/CBP and TRAP220, as
these coregulators have been shown to have roles in adipoge-
nesis [31, 71]. An increase in lipolysis is observed in TIF2−/−
cells, indicating a reduced potential for the storage of fatty
acids. Furthermore, a TIF2 dose-dependent attenuation of
the PGC-1α/PPARγ activation complex in the presence of
SRC-1 suggests that TIF2 competes with SRC-1 for the for-
mation of PGC-1α/PPARγ complexes. However, TIF2 does
notsigniﬁcantlyenhancePPARγ transactivationmediatedby
PGC-1α, and an increase in PGC-1α expression level was ob-
served in BAT of TIF2−/− mice [50]. Thus, TIF2 appears to
be linked to WAT diﬀerentiation and fat storage by potenti-
ating PPARγ activity (Figure 1). In contrast, SRC-1−/− mice
displayed increased fat mass and plasma leptin levels. More-
over, the mRNA of UCP-1, PGC1α, and AOX were decreased
in BAT, suggesting that the thermogenic machinery in BAT
is diminished in the absence of SRC-1. Thus, SRC-1 largely
contributes to brown fat diﬀerentiation and energy expendi-
ture in brown fat (Figure 1).
A recent study involving p/CIP−/− SRC-1−/− double
knockout (DKO) mice revealed that p/CIP and SRC-1 are
required for induction of genes necessary for adaptive ther-
mogenesis and lipid storage in BAT [51]. These DKO mice
consumemorefood, bothonchow andhighfatdiets, asare-
sult of decreased blood leptin levels; however, the DKO mice
are resistant to diet-induced obesity and remain lean when
compared to single knockout and wild type littermates. Fur-
thermore, these mice are more physically active and have in-
creased basal metabolic rates. This phenotype appears to be
the result of failed induction of PPARγ target genes, result-
ing in increased basal metabolism and decreased adipogen-
esis [51]. Although p/CIP single knockout mice do not ex-
hibit a strong phenotype in adipogenesis, p/CIP appears to
potentiate SRC-1-mediated fat storage in BAT and perhaps
adaptive thermogenesis (Figure 1).
2.3. TheSWI/SNFchromatinremodelingcomplexis
requiredforinductionofthePPARγ promoter
andadipogenesis
The mammalian SWI/SNF (mating type switching/sucrose
nonfermenting)familyofATP-dependentchromatinremod-
eling enzymes plays critical roles in the activation of PPARγ
transcription for adipogenesis. The core components of the
complex include either the Brg1 or Brm ATPase and sev-
eral Brg1/Brm-associated factors (BAFs). Although in vitro
analyses of SWI/SNF complexes containing Brg1 or Brm re-
veal similarities in chromatin remodeling [72], diﬀerences in
their functions have been observed in vivo. Brg1 knockout
mice are embryonically lethal, and heterozygotes show a pre-
disposition for tumor development [73]. In contrast, Brm
knockout mice and cells show only a slight diﬀerence in pro-
liferation from wild type [74].
PBAF, a multisubunit complex containing Brg1 and
BAF180 subunit was shown to activate PPARγ transcrip-
tion in an in vitro chromatin-based system [75]. The neces-
sity of the SWI/SNF chromatin remodeling complex is illus-
trated by experiments revealing that Pol II and general tran-
scription factors are dissociated from the PPARγ promoter
when cells are transfected with dominant negative compo-
nents of the SWI/SNF complex [25]. This suggests that func-
tion of the SWI/SNF complex is essential to formation of the
preinitiation complex (PIC) on the PPARγ2p r o m o t e ra n d
subsequent transcription initiation. Expression of dominantEmily Powell et al. 5
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Figure 1: Putative functions of PPARγ cofactors in white adipose- and brown adipose-modulated lipid and energy metabolism. Positive
regulators are highlighted in red. Preadipocytes can be diﬀerentiated into white adipocytes via transcriptional regulation of PPARγ by coac-
tivators CBP and TRAP220, or diﬀerentiated into brown adipocytes via transactivation by PGC-1β,P G C - 1 α, and SRC-1. TIF2 plays roles in
lipid storage from white adipocytes, while p/CIP and SRC-1 function to promote lipid storage in brown fat. PGC-1α is not only involved in
adaptive thermogenesis but it also promotes the conversion of white adipocytes into brown adipocytes. SRC-1 is the only member of p160
proteins that show clear function in energy expenditure.
negative Brg1 or hBrm leads to blocked induction of the
PPARγ activatorandadipogenesis,whichwasmeasuredboth
morphologicallyandbyexpressionoftwoadipogenicmarker
genes, aP2 and adipsin [25]. Because Brg1 and hBrm are
both crucial members of the SWI/SNF chromatin remod-
eling complex, this evidence suggests that the SWI/SNF en-
zymes are required for the activation of PPARγ and adipoge-
nesis [25].
BAF60c, another component of the SWI/SNF complex,
serves to anchor the SWI/SNF complex to PPARγ.G S Tp u l l -
down experiments as well as co-IP conﬁrmed the ability of
BAF60c to interact with PPARγ. Moreover, BAF60c inter-
acts with PPARγ in a ligand-dependent fashion to enhance
the transcriptional activity of the receptor [26]. However,
BAF60c was not shown to aﬀect adipocyte diﬀerentiation in
theseexperimentssuggestingthatBAF60cisnottheonlyfac-
tor docking SWI/SNF to PPARγ [26].
2.4. TRAP220/DRIP205/PBPisrequiredfor
transactivationofPPARγ2andadipogenesis
The TRAP complex has been implicated as a general trans-
activator of nuclear receptors [76], apparently function-
ing by direct interaction with DNA-bound activators and
R N Ap o l y m e r a s eI I[ 30]. Appreciable evidence for the TRAP
complex serving as a coactivator for PPARγ is derived from
an in vitro transcription assay in which puriﬁed TRAP com-
plex signiﬁcantly enhanced the transcriptional activity of
PPARγ2 on a PPRE-template. GST pull-down assays con-
ﬁrmed the ability of the TRAP complex to bind PPARγ2
only in the presence of TRAP220 [31]. Thus, TRAP220, also
known as DRIP205 and PBP [77], anchors the TRAP com-
plex to PPARγ target promoters. A TRAP220−/− mutation
is embryonically lethal at day 11.5, showing defects in vas-
cular development similar to those in PPARγ−/− mice, indi-
cating that TRAP220 function is nonredundant and essen-
tial for development [54, 78]. Studies using immortalized
TRAP220−/− MEFs reveal that TRAP220 acts as a coactivator
forPPARγ2andisanessentialmediatorofadipogenesis[31].
TRAP220−/− cells exhibit defective PPARγ2-stimulated adi-
pogenesis and expression of adipogenic marker genes. These
adipogenic defects can be rescued by ectopic expression of
TRAP220 [31]. These data support the model that TRAP220
acts as an anchor in TRAP complex binding, and may also
play a role in binding to the CBP-associated complex.
2.5. Evidenceofamegacomplexin
PPARtransactivation
PPAR interacting protein PRIP/NRC/RAP250/TRBP is ubiq-
uitously expressed in adult mice, and binds to PPARγ en-
hancing ligand-dependent transcription [55, 56, 79]. PRIP is
also necessary for embryonic vascular development, as well6 PPAR Research
as normal cardiac and neural development, as shown by a
lethal null mutation [56, 57]. Mouse embryonic ﬁbroblasts
isolated from these PRIP null mice exhibited a decreased
capacity for ligand-dependent transcriptional activation of
PPARγ [56, 57]. PRIP interacting protein with methyltrans-
ferase domain (PIMT) was isolated in a yeast two-hybrid
screen using PRIP as bait and enhances PRIP-mediated
PPARγ transactivation [80]. Interestingly, PIMT binds to
CBP/p300 and TRAP220 supporting a model in which the
TRAP complex anchored by TRAP220 is bound to PPAR at
the same time as the CBP/p300-associated complex [81].
The isolation of PPARα-interacting cofactor (PRIC)
complex which enhances the transcription of PPARα further
supports the existence of megacomplex on PPAR-target gene
promoters [82]. Of the 25 polypeptides comprising PRIC
complex, 18 contained one or more LXXLL motifs. Recog-
nized proteins identiﬁed in the PRIC complex include SRC-
1, CBP, TRAP220, PRIP, PIMT, TRAP100, and PGC-1, sug-
gesting that CBP-associated complex and TRAP220 bound
basal transcription factors may be bound simultaneously.
PRIC285, a novel member of the PRIC complex renamed
PPAR DNA-binding domain interacting protein (PDIP-1),
was shown to bind to the DBD of PPARγ in a yeast two-
hybridassay.Twosplicevariants,PDIP-1aandPDIP-1b,were
identiﬁed,andbothwereshowntotransactivateallthreeiso-
typesofPP ARandth yroidreceptor ,whereasPDIP -1abutnot
PDIP-1b transactivates estrogen receptor (ER) α and andro-
gen receptor (AR), indicating some receptor speciﬁcity [82].
3. COREPRESSORS
3.1. CorepressorRIP140regulatesenergy
metabolismbutnotadipogenesis
RIP140 was originally identiﬁed as a corepressor of ligand-
dependent ER function by binding to the AF-2 domain [83].
It was later shown to bind to PPARα in a yeast two-hybrid
screen [84]. Although PPARγ and RXR ligands promote the
interaction of RIP140 with rat PPARγ in solution, RIP140
interaction with PPARγ/RXR heterodimers does not occur
on DNA. This cofactor downregulates the activity of several
nuclear receptors speciﬁcally by attenuating transactivation
mediated by SRC-1. For instance, RIP140 competes with the
coactivator SRC-1 for binding to PPARγ [84]. This evidence
is suggestive of a model in which RIP140 indirectly regulates
the activity of PPARγ by competing with coactivators such
as SRC-1. RIP140−/− mice exhibit upregulation of energy
metabolic genes UCP-1 and carnitine O-palmitoyl trans-
ferase I (CPT-I) and increased β-oxidation in adipocytes, al-
beit adipogenesis is unaﬀected [58]. This data suggests that
a highly speciﬁc set of PPARγ mediated functions is modu-
latedbyRIP140repressionwhileotherPPARγ functionssuch
as adipogenesis remain unaltered.
3.2. TranscriptionalcorepressorsforPPARγ:
NCoRandSMRT
NCoR and SMRT function to recruit HDAC (histone dea-
cetylase) complexes, which covalently modify nucleosomes
to compact DNA and repress transcription [47]. Binding of
NCoR and SMRT to NRs is mediated by the corepressor nu-
c l e a rr e c e p t o rb o x( C o R N R )[ 85]. This motif is very simi-
lar to the NR box with a consensus sequence of hydropho-
bic residues including leucine and isoleucine [86, 87]. The α-
helix that contains the CoRNR box is predicted to be longer
than the helix containing the NR box in coactivators [87],
presenting a possible mechanism for cofactor selection via
the ligand-induced conformational change of the NR. Thus,
conformational change may exclude corepressors from the
AF-2 binding pocket.
Evidence exists suggesting that in the absence of lig-
and, PPARγ recruits the transcriptional corepressors NCoR
and SMRT to downregulate PPARγ-mediated transcrip-
tional activity. Gene silencing of NCoR or SMRT in 3T3-
L1 preadipocytes has been shown to increase adipocyte dif-
ferentiation, a classical PPARγ2f u n c t i o n[ 42]. Moreover,
treatment with the synthetic PPARγ ligand pioglitazone de-
creases both PPARγ-SMRT and PPARγ-NCoR interactions,
although the PPARγ-SMRT interaction decrease is much
more prominent. Furthermore, in a separate study by Krogs-
dam et al., repression of PPARγ-mediated transcription by
NCoR exists even in the presence of ligand [88]. These stud-
ies underscore the transcriptional repression of PPARγ by
NCoR and SMRT in vivo.
It appears that gene-speciﬁc factors may aﬀect the
conformation of PPARγ, further complicating the ligand-
receptor-repressor interaction. One example of this variabil-
ity is the diﬀerential activation of glycerol kinase (GyK) and
aP2 transcription. Although both contain PPREs, PPARγ re-
cruits corepressor NCoR to the GyK gene while recruiting
coactivators to the aP2 gene [89]. The addition of TZD re-
sults in the activation of GyK by recruiting PGC-1α and dis-
placing NCoR, while TZD treatment has little eﬀect on tran-
scription of aP2 and does not recruit PGC-1α to the aP2 pro-
moter [89]. These data suggest that gene-speciﬁc PPARγ re-
ceptor conformation leads to the recruitment of diﬀerent co-
factor complexes.
Another corepressor, Sirt1, has also been shown to ef-
fectively inhibit PPARγ-mediated transcription [90]. This
NAD-dependent deacetylase binds to NCoR and SMRT, pre-
senting a model where Sirt1 is recruited to PPARγ via in-
teractions with NCoR and/or SMRT. This was further sup-
ported by loss of Sirt1-mediated repression when NCoR lev-
els were decreased via RNAi [90].
3.3. Summaryofcoactivatorsandcorepressors
inlipidandenergymetabolism
Cellular energy metabolism is maintained through a del-
icate balance between energy intake and energy expendi-
ture. When energy intake exceeds energy expenditure, ex-
cess energy is stored as lipid in WAT. Although BAT also
allows storage of small amount of lipids, it is mainly re-
sponsible for energy dissipation. As PPARγ plays an essential
role in lipid homeostasis, it is not surprising that multiple
PPAR cofactors are involved in lipid and energy metabolism;
namely, processes including adipocyte diﬀerentiation, lipid
storage, and adaptive thermogenesis (Figure 1). PPARγ/RXREmily Powell et al. 7
heterodimers are master regulators of preadipocyte diﬀeren-
tiation into brown and white adipocytes. Multiple lines of
evidence support the model that CBP/p300 and TRAP220
participate in white adipocyte diﬀerentiation, and this pro-
cess is reversibly regulated by corepressors NCoR and SMRT
[31,42,71].Onthecontrary,diﬀerentiationofpreadipocytes
into BAT is regulated by a diﬀerent set of coactivators such as
PGC-1β/PGC-1α and SRC-1 [50, 52]. Conversion of white
adipocyte to brown adipocyte-like cells can be at least par-
tially catalyzed by ectopically expressed PGC-1α [62]. TIF2
playsimportantfunctionsinthestorageoffattyacidsinWAT
as evident by the fact that TIF2−/− mice are protected from
obesity and TIF2−/− cells show an increase in lipolysis [50].
Brown adipocytes are enriched in mitochondria and the ma-
jor function is adaptive thermogenesis in rodents. PGC-1α
and SRC-1 are positive regulators of the thermogenic capac-
ity of BAT [50, 52, 53], whereas the corepressor RIP140 ap-
pears to negatively regulate this process [58]. Lipid storage in
brownadipocytescanberegulatedbycoactivatorsp/CIPand
SRC-1 [51]. Figure 1 summarizes some of the major players
in lipid and energy homeostasis based on current literature.
It is worthy to note that some cellular processes require more
stringent regulation than others, such that more than one
memberofthecloselyrelatedproteinsaresimultaneouslyin-
volved. For example, complementary actions of p/CIP and
SRC-1 in lipid storage of brown adipocytes and two PGC-1
coactivators in brown fat diﬀerentiation are absolutely essen-
tial.
3.4. Ligand-andpromoter-speciﬁccoregulator
recruitmentinPPARγ transactivation
AcomparisonofnaturalandsyntheticPPARγ ligandsreveals
adistinctdiﬀerentialrecruitmentoftranscriptionalcoactiva-
tors. 15d-PGJ2, an endogenous PPARγ ligand, is capable of
inducing interactions between the PPARγ/RXR heterodimer
and SRC-1, TIF2, p/CIP, p300, and TRAP220 [91]. However,
the synthetic PPARγ ligand troglitazone did not induce in-
teraction between the PPARγ/RXR heterodimer and any of
thesecoactivators.Furthermore,thetransactivationfunction
of PPARγ was shown to be increased by these coactivators
in the presence of 15d-PGJ2 and 9-HODE, but not troglita-
zone. FK614, a non-TZD synthetic PPARγ ligand, and two
TZDs, rosiglitazone and pioglitazone, induce recruitment of
SRC-1, CBP, and PGC-1α when bound to PPARγ.H o w e v e r ,
the level to which SRC-1 and CBP are recruited by FK614-
bound PPARγ is altered in comparison to rosiglitazone- and
pioglitazone-bound receptor (Fujimura, 2005) while PGC-
1α showed similar levels of recruitment. These data suggest
speciﬁc ligands can diﬀerentially deﬁne the coactivator com-
plex, and that similar coactivators might have distinct in vivo
functions.
4. CONCLUSIONS
The race to ﬁnd new nuclear receptor coactivators and core-
pressors has resulted in a rapid increase in the number of
known cofactors accompanied by insuﬃcient knowledge as
totheirmechanismsofinteractionandtranscriptionalmedi-
ation. Initial investigation has shown that seemingly redun-
dant or promiscuous cofactors have a high amount of con-
text speciﬁcity. Gene sequence- and ligand-speciﬁc nuclear
receptor conformation appears to aﬀect cofactorcomplex re-
cruitment. The relative expression levels of coactivators and
corepressors modulate nuclear receptor transactivation. In
the case of PPARγ, there are only a few examples of these
diﬀerential conditions thus far. Further investigation of these
interactionsmayeventuallyallowforabettercomprehension
of context-speciﬁc expression proﬁles. Partial PPARγ ago-
nists, such as FK614, that diﬀerentially activate PPARγ tar-
get genes may be eﬀective in treating metabolic disease while
reducing the side eﬀects (e.g., promoting obesity) caused by
current TZD-based treatments. The ability to target unique
expressionproﬁlesmayalsoleadtoamorewidespreadability
to treat illnesses related to nuclear receptor function.
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GST: Glutathione s-transferase
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PPRE: PPAR-response element
PRIC: PPARα-interacting cofactor
PRIP: PPAR interacting protein
PRMT: Protein arginine methyltransferase
RAP: Receptor-associated protein
RIP140: Receptor interacting protein 140
RRM: RNA-recognition motif
RXR: Retinoid X receptor
Sirt1: Sirtuin 1
SMRT: Silencing mediator of retinoid and
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SRC: Steroid receptor coactivator
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TBL1: Transducin β-like 1
TBLR1: Transducin β-like related 1
TIF: Transcriptional intermediary factor
TRAP: Thyroid receptor-associated protein
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